GlassScriptPhysician profile
Kara J Nance
NPI 1346295763
$4,160.38
in general payments reported to CMS, 2019-2025
27 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $610 · 2021: $618 · 2022: $371 · 2023: $559 · 2024: $746 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,007.49 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $477.55 | 2021-2024 | |
| Lilly USA, LLC | $452.32 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $331.08 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $296.42 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Corcept Therapeutics | $280.68 | 2024-2025 | Korlym |
| Currax Pharmaceuticals LLC | $258.44 | 2020-2024 | Contrave |
| Allergan, INC. | $189.08 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.47 | 2021-2023 | |
| Eisai INC. | $114.42 | 2019 | |
| Astellas Pharma US INC | $102.16 | 2021-2025 | Veozah |
| Vivus LLC | $91.22 | 2019-2023 | Qsymia |
| Idorsia Pharmaceuticals US INC | $80.42 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $53.63 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.02 | 2019-2024 | Jardiance, Synjardy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $35.45 | 2024 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $28.90 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $26.01 | 2022 | |
| Merck Sharp & Dohme LLC | $24.82 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.76 | 2021 | |
| Radius Health, INC. | $20.04 | 2025 | Tymlos |
| Madrigal Pharmaceuticals | $19.17 | 2025 | Rezdiffra |
| Nalpropion Pharmaceuticals LLC | $18.17 | 2019 | |
| Mylan Specialty L.P. | $14.87 | 2024 | Yupelri |
| Echosens North America, INC. | $14.65 | 2025 | Fibroscan |
| Philips North America LLC | $13.15 | 2024 | (Ck7) Extended Holter |
| Biohaven Pharmaceutical Holding Company LTD. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Nance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.